Merck-Pandion acquisition: re-balancing immune response to treat autoimmune disease
Merck has acquired Pandion Therapeutics for $1.85bn. The deal centres around Pandion’s TALON technology and immune modulators, which re-balance the…
By
M&As
Latest in
M&As
Horizon acquires Viela for $3bn to drive innovation and long-term growth
Horizon has agreed to buy Viela for $3bn to expand its pipeline, as well as drive long-term growth. Viela has…
By
Pharma November deals snapshot
Consolidation in the pharmaceutical sector, with the biggest November deals happening in the US, was given a boost by China…
Merck acquires VelosBio: exploring the promise of ROR1 in cancer
Merck has signed a definitive agreement to acquire VelosBio. The $2.75bn deal hinges around VelosBio’s ROR1-targeting antibody therapies, and particularly…
By
Treating food allergies: Nestlé Health Science’s $2.6bn acquisition of Aimmune
In January, Aimmune’s Palforzia became the first drug approved for any food allergy. Nestlé Health Science, which has been involved…
By
Century acquires Empirica: treating GBM with off-the-shelf cell therapies
By acquiring Empirica and its work on glioblastoma (GBM), Century Therapeutics has taken its first step towards developing off-the-shelf cell…
By
Novo Nordisk moves further into CV diseases with Corvidia acquisition
Cardio-renal specialist Corvidia Therapeutics has been acquired for $725m by diabetes giant Novo Nordisk. This deal builds on Novo Nordisk’s…
By
AbbVie acquires Allergan: unpicking the year-long approval process
AbbVie’s $63bn acquisition of Allergan has been in the works since June 2019. It aims to diversify AbbVie’s portfolio beyond…
By